Estimated times of divergence of cerebrospinal fluid biomarkers vary from 18 years for Aβ42 to six years for cognitive decline
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 21, 2024 (HealthDay News) — Cerebrospinal fluid (CSF) and other biomarkers differ for individuals with Alzheimer disease and cognitively normal controls, with the estimated times of divergence varying from 18 to six years before diagnosis, according to a study published in the Feb. 22 issue of the New England Journal of Medicine.
Jianping Jia, M.D., Ph.D., from Xuanwu Hospital in Beijing, and colleagues conducted a multicenter, nested case-control study of Alzheimer disease biomarkers in cognitively normal individuals. At two- to three-year intervals, a subgroup of these participants underwent CSF testing, cognitive assessments, and brain imaging. A total of 648 participants in whom Alzheimer disease developed were matched with 648 participants with normal cognition.
Participants were followed for a median of 19.9 years. The researchers found that CSF and imaging biomarkers in the Alzheimer disease group diverged from those in the cognitively normal group a number of years before diagnosis: amyloid-beta (Aβ)42 at 18 years; ratio of Aβ42 to Aβ40 at 14 years; phosphorylated tau 181 at 11 years; total tau at 10 years; neurofilament light chain at nine years; hippocampal volume at eight years; and cognitive decline at six years. The changes in CSF biomarker levels in the Alzheimer disease group initially accelerated and then slowed as cognitive impairment progressed.
“The importance of the work by Jia et al. cannot be overstated,” Richard Mayeux, M.D., from Columbia University in New York City, writes in an accompanying editorial. “Knowledge of the timing of these physiological events is critical to provide clinicians with useful starting points for prevention and therapeutic strategies.”
Editorial (subscription or payment may be required)
Copyright © 2024 HealthDay. All rights reserved.
